SNBP - IPO Update: Sun BioPharma Presents IPO Terms
Quick Take
Sun BioPharma (SNBP) intends to raise $10 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing a treatment candidate for pancreatic cancer.
SNBP is a thinly capitalized firm operating in a very difficult area of research, where major pharma firms have invested far greater sums and failed to develop effective treatments, so I'll pass on the IPO.
Company & Technology
Waconia, Minnesota-based Sun was founded to develop a single polyamine metabolic inhibitor for patients with pancreatic cancer.
Management is headed